Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Gastro-enteropancreatic neuroendocrine tumor 3Neuroendocrine Tumors 2Stomach Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Pancreatic Diseases 1Neuroectodermal Tumors 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 33-Iodobenzylguanidine 3Magnetic Resonance Spectroscopy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1olaparib 1fludarabine phosphate 1copper dotatate CU-64 1cabozantinib 1atezolizumab 1Specimen Handling 1Lutetium-177 1Lutetium 1Iodine-131 1Interleukin-13 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Cyclophosphamide 1Biopsy 190Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)- 13-fluorobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraganglioma × Lutetium × NET × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡